Loading...
•
Jun 30, 2024
Phibro Q4 2024 Earnings Report
Phibro's financial performance showed strength in Q4 2024, with revenue growth across segments and strategic initiatives underway.
Key Takeaways
Phibro Animal Health Corporation reported a 7% increase in net sales for the fourth quarter ended June 30, 2024, reaching $273.2 million. Net income decreased to $0.8 million, with diluted earnings per share at $0.02. Adjusted EBITDA increased by 3% to $33.4 million, and adjusted diluted EPS increased by 10% to $0.41. The company provided financial guidance for fiscal year 2025, projecting net sales between $1.040 billion and $1.090 billion and adjusted EBITDA between $118 million and $126 million.
Net sales increased by 7% to $273.2 million, driven by growth in Animal Health and Mineral Nutrition segments.
Net income decreased to $0.8 million, with diluted earnings per share at $0.02.
Adjusted EBITDA increased by 3% to $33.4 million, reflecting improved performance in Animal Health, Mineral Nutrition, and Performance Products.
The company is focused on Phibro Forward initiative to boost revenue growth and cost savings, with anticipated benefits in fiscal year 2025.
Phibro
Phibro
Phibro Revenue by Segment
Revenue by Segment
Animal Health Revenue
CapyFin.comMFAs and Other Revenue
CapyFin.comNutritional Specialties Revenue
CapyFin.comVaccines Revenue
CapyFin.comMineral Nutrition Revenue
CapyFin.comPerformance Products Revenue
CapyFin.com Forward Guidance
Phibro provided financial guidance for the year ending June 30, 2025, expecting net sales of $1.040 billion to $1.090 billion and adjusted EBITDA of $118 million to $126 million.
Positive Outlook
- Continued growth in Animal Health business
- Recovery in Mineral Nutrition
- Recovery in Performance Products
- Net income of $32 million to $38 million
- Adjusted net income of $50 million to $56 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income